Cardiovascular Trials

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).

If you would like additional information regarding this trial, please contact researchopportunities@prairieresearch.com

The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.

If you would like additional information regarding this trial, please contact researchopportunities@prairieresearch.com

Study to characterize real-world outcomes of patients receiving the commercially available Amulet device in the United States.

Study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs.

A study to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.

If you would like additional information regarding this trial, please contact researchopportunities@prairieresearch.com

Study  to determine if personalized rate pacing and tachycardia remodeling pacing can favorably remodel HFpEF patients by increasing chamber volume.

If you would like additional information regarding this trial, please contact researchopportunities@prairieresearch.com

Study to evaluate the safety and efficacy of the Alleviant System for no-implant interatrial shunt creation in patients with chronic heart failure.

If you would like additional information regarding this trial, please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT04592445?cond=rebalance+hf&draw=2&rank=1

A research study to look at how well CagriSema works compared to placebo for reducing the risk of heart failure worsening and death in people with heart failure with preserved or mildly reduced ejection fraction and obesity.

If you would like additional information regarding this trial, please visit the website below or contact researchopportunities@prairieresearch.com